drugset
drugset / Trial / NCT06821464

A Trial of HRS-9813 in Healthy Subjects

NCT06821464 ↗

Phase 1 Completed 45 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.

Timeline

Start
2025-02-17
Primary completion
2025-07-27
Completion
2025-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9813 Unknown — Oral

Indications

idiopathic pulmonary fibrosis